

|                     |                                   |                  |              |
|---------------------|-----------------------------------|------------------|--------------|
| <b>Policy Name:</b> | <b>Acthar Gel (corticotropin)</b> | <b>Policy #:</b> | <b>1742P</b> |
|---------------------|-----------------------------------|------------------|--------------|

## Purpose of the Policy

The purpose of this policy is to establish the criteria for coverage of Acthar Gel.

## Statement of the Policy

Health Alliance Medical Plans and Health Alliance Northwest will approve the use of Acthar Gel under the specialty pharmacy benefit when the following criteria have been met.

## Criteria

### 1. Criteria for Coverage for West Syndrome (infantile spasms)

- 1.1 Documentation of West Syndrome
- 1.2 Documentation showing that member is less than 2 years of age
- 1.3 Approval period: 4 week treatment regimen within a 6 month approval duration
- 1.4 Reauthorization requires documentation that member shown substantial clinical benefit from therapy

### 2. Excluded Diagnoses

- 1.5 The use of Acthar for the treatment of acute exacerbations of multiple sclerosis is not considered medically necessary.
  - Acthar gel showed no clinical benefit, greater number of adverse effects, and required longer duration of treatment vs. IV methylprednisolone
  - Acthar gel administered either intramuscularly or subcutaneously at a dose of 80 U/day for 5 days. No significant treatment difference was observed. No direct comparison to methylprednisolone performed.
  - Health Alliance does not consider known adverse events associated with corticosteroid use to be a contraindication preventing future use.
- 1.6 FDA labeling suggests that H.P. Acthar may be useful in the following conditions, but it is not FDA-indicated. H.P. Acthar is unproven and not medically necessary in the following situations
  - Testing of adrenocortical function
    - Use cosyntropin instead
  - Musculoskeletal Disorders:
    - As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis.
  - Skin Diseases:
    - During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis).
  - Dermatologic Diseases:
    - Severe erythema multiforme, Stevens-Johnson syndrome, atopic dermatitis
  - Serum sickness
  - Eye Diseases:
    - Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis; iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis; anterior segment inflammation.
  - Lung Diseases:
    - Symptomatic sarcoidosis.

- Diuresis in nephrotic syndrome:
  - To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
- Any indication outside of infantile spasms

## CPT Codes

|  |  |
|--|--|
|  |  |
|--|--|

## HCPCS Codes

|  |  |
|--|--|
|  |  |
|--|--|

## References

1. Acthar Gel (repository corticotropin injection) [prescribing information]. Bedminster, NJ: Mallinckrodt ARD LLC. October 2021.
2. Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology* 2012; 78:1974.
3. Hamano S, Yamashita S, Tanaka M, et al. Therapeutic efficacy and adverse effects of adrenocorticotrophic hormone therapy in west syndrome: differences in dosage of adrenocorticotrophic hormone, onset of age, and cause. *J Pediatr* 2006; 148:485.
4. Bellutti Enders F, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. *Ann Rheum Dis*. 2017;76(2):329-340.
5. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78(6):736-745.
6. Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotrophic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. *Drug Des Devel Ther*. 2011;5:381-389.
7. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. *Neurology*. 1989;39(7):969–971
8. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;58(6):2004079.
9. American Academy of Allergy, Asthma and Immunology (AAAAI); American College of Allergy, Asthma and Immunology (ACAAI); Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. *Ann Allergy Asthma Immunol*. 2010;105(4):259-273.
10. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;58(6):2004079.
11. Bellutti Enders F, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. *Ann Rheum Dis*. 2017;76(2):329-340.
12. Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. *Br J Dermatol*. 2016;174(6):1194-1227.
13. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. *Ann Rheum Dis*. 2020;79(6):713-723.
14. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2021;73(7):924-939.
15. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. *Kidney Int*. 2021;100(4S):S1-S276.

16. McGrath ER, Doughty CT, Amato AA. Autoimmune myopathies: updates on evaluation and treatment. *Neurotherapeutics*. 2018;15(4):976-994.
17. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol*. 2020;82(6):1445-1486.
18. National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. NICE clinical guideline CG186. London, UK: National Institute for Health and Care Excellence; October 2014. [nice.org.uk/guidance/cg186](http://nice.org.uk/guidance/cg186).
19. Sidbury R, Davis DM, Cohen DE, et al; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol*. 2014;71(2):327-349.
20. Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheumatol*. 2019;71(1):5-32.
21. Trayer KP, Love G, Studdiford JS. Erythema multiforme: recognition and management. *Am Fam Physician*. 2019;100(2):82-88.[
22. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Care Res (Hoboken)*. 2019;71(10):1285-1299.
23. Yang SH, Chang C, Lian ZX. Polymyositis and dermatomyositis - challenges in diagnosis and management. *J Transl Autoimmun*. 2019;2:100018

Created Date: 11/18/10

Effective Date: 11/18/10

Posted to Website: 01/01/2022

Revision Date: 08/02/2023

#### DISCLAIMER

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.